CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors

CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, announced the appointment of Tony Coles, M.D., to the company’s Board of Directors, according to a Business Wire press release.

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School. He earned his M.D. from Duke University, a master’s degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University.

Read the full press release here.